

Akers Biosciences, Inc.
("Akers" or the "Company")

Acquisition of WNCK, Inc.

Akers Biosciences, Inc. (LSE.AKR) is pleased to announce that it has successfully completed the acquisition of the assets of WNCK, Inc., ("WNCK") of The Woodlands, Texas, USA, for a total consideration of \$563,000 to be satisfied as to \$410,000 in cash and other considerations and through the issuance of 125,000 shares.

WNCK is the leading distributor of disposable alcohol breathalyzers in the U.S. Its Breath Scan product line has been one of the industry standards for the past 15 years. WNCK's customer base includes law enforcement agencies, retail chains, and the U.S. military. Akers has been the sole manufacturer of WNCK's products for the past 5 years.

Akers will benefit from the significantly increased margin and distribution channels of its alcohol breathalyzer products, resulting from the purchase of this distributor. In addition to being profit-enhancing from the day of acquisition, this transaction will establish the Company as the premier force in portable alcohol breathalyzers in the U.S. and attractive cost savings are likely to arise from the swift, full integration of WNCK's operation into Akers.

The acquisition will give The Company access to a broader client base. This is especially important in view of the rapidly expanding market resulting from new Coast Guard regulations and military programs. With the acquisition of WNCK, The Company is well positioned to profit from this growing market.

Akers expects the acquisition costs to be recouped within 18 months through increased margins and greater unit sales.

Dr. Ray Akers, CEO of Akers Biosciences, Inc. said,

"We are very pleased to add the highly established Breath Scan product line of WNCK to our Breath Alcohol Check line of alcohol breathalyzers. Together, Akers and WNCK will command a strong presence in the market place. We have been very successful at organically growing our own business, and welcome the opportunity to enhance this complementary product line.

We are confident that the Breath Scan products will make a positive financial contribution to our Company in the current year."

Enquiries:

Dr. Raymond Akers	Chief Executive Officer, Akers Biosciences, Inc.	020 7917 9476
Paul Freedman	Chief Financial Officer, Akers Biosciences, Inc.	001 856 848 8698
Bill Roberts	CTC, Inc.	001 937 434 2700
Ben Simons	Hansard Communications	020 7245 1100/07713090135

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.